CME - Continuing Medical Education
Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and International Society for Cell & Gene Therapy. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 15.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Objectives - After Attending This Program You Should Be Able To
- Identify the scientific, clinical, laboratory, technology, funding and regulatory issues related to specific types of cell-based research/therapy. Demonstrate cross–disciplinary participation from clinicians, laboratory personnel, regulatory professionals, scientists, technology and business experts from both academia and industry.
- Describe the translational aspects of and issues involved with cell and tissue-based therapies. Translate information and experience from more mature cellular therapy areas such as hematopoietic stem cell transplantation to emerging applications including non-hematopoietic indications.
- Promote the transfer of information and experience from senior practitioners to young scientists in the field. Advance rigorous evaluation of quality, safety and efficacy of novel cellular, gene-modified cell and tissue-based therapies.